FY2022 EPS Estimates for Taysha Gene Therapies, Inc. Decreased by Analyst (NASDAQ:TSHA)

Taysha Gene Therapies, Inc. (NASDAQ:TSHAGet Rating) – Equities researchers at Wedbush lowered their FY2022 earnings per share estimates for shares of Taysha Gene Therapies in a research report issued on Tuesday, May 17th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($4.15) for the year, down from their prior estimate of ($3.86). Wedbush also issued estimates for Taysha Gene Therapies’ Q4 2022 earnings at ($0.90) EPS, FY2024 earnings at ($3.14) EPS, FY2025 earnings at ($1.85) EPS and FY2026 earnings at ($1.45) EPS.

Other research analysts have also issued research reports about the stock. Wells Fargo & Company started coverage on shares of Taysha Gene Therapies in a research note on Tuesday, March 1st. They set an “overweight” rating and a $25.00 target price for the company. JMP Securities lowered their target price on shares of Taysha Gene Therapies from $44.00 to $36.00 and set a “market outperform” rating for the company in a research note on Friday, April 1st. Sumitomo Mitsui Financial Group started coverage on shares of Taysha Gene Therapies in a research note on Friday, February 18th. They set an “outperform” rating and a $25.00 target price for the company. Truist Financial lowered their target price on shares of Taysha Gene Therapies from $60.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, April 1st. Finally, Guggenheim lowered their target price on shares of Taysha Gene Therapies to $22.00 and set a “na” rating for the company in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $29.64.

Shares of TSHA stock opened at $3.03 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.08 and a quick ratio of 3.08. The firm has a market cap of $122.64 million, a PE ratio of -0.60 and a beta of 2.23. The company has a 50-day moving average of $5.16 and a two-hundred day moving average of $8.82. Taysha Gene Therapies has a 1-year low of $2.69 and a 1-year high of $26.99.

Taysha Gene Therapies (NASDAQ:TSHAGet Rating) last announced its quarterly earnings data on Monday, May 16th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.28). During the same quarter in the previous year, the firm earned ($0.87) EPS.

A number of large investors have recently modified their holdings of TSHA. Royal Bank of Canada raised its holdings in Taysha Gene Therapies by 75.1% during the second quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $32,000 after purchasing an additional 657 shares in the last quarter. Macquarie Group Ltd. acquired a new stake in Taysha Gene Therapies during the third quarter worth approximately $41,000. Citigroup Inc. raised its holdings in Taysha Gene Therapies by 142.2% during the third quarter. Citigroup Inc. now owns 3,321 shares of the company’s stock worth $62,000 after purchasing an additional 1,950 shares in the last quarter. Sargent Investment Group LLC acquired a new stake in Taysha Gene Therapies during the first quarter worth approximately $69,000. Finally, Wells Fargo & Company MN acquired a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $110,000. 46.05% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies (Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Further Reading

Earnings History and Estimates for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.